What is Intellia Therapeutics's financing cash flow?

Intellia Therapeutics (NTLA) reported financing cash flow of $33.57M in Q1 2026.

What is the long-term trend for Intellia Therapeutics's financing cash flow?

Over 4 years (2021 to 2025), Intellia Therapeutics's financing cash flow has grown at a -35.0% compound annual growth rate (CAGR), from $736.69M to $131.49M.

What does financing cash flow mean?

Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Intellia Therapeutics NTLA Financing Cash Flow

Financing Cash Flow at other companies

Ionis PharmaceuticalsIONS

$57.26M+2,504%

ALN

Alnylam PharmaceuticalsALNY

$15.71M-65.9%

CRISPR TherapeuticsCRSP

$591.91M+5,490%

Beam TherapeuticsBEAM

$96.61M-79.6%

Iovance Biotherapeutics, Inc.IOVA

$94.34M-34.2%

Viridian Therapeutics, Inc.VRDN

$6.36M-31.0%

Other financials

Income statement

See full

Revenue$15.0M-9.5%

Operating income-$100.5M+16.8%

Net income-$96.2M+15.8%

EPS (diluted)-$0.81+26.4%

Balance sheet

See full

Cash & equivalents$134.7M+6.2%

Total debt$80.5M-32.5%

Total equity$620.9M-20.4%

Total assets$758.8M-23.1%

Cash flow

See full

Operating cash flow-$117.3M+21.2%

CapEx$79.0K-89.3%

Free cash flow-$117.4M+21.5%

Valuation

See full

Market cap$2.17B+106%

Profitability

See full

Operating margin-636.6%-202pp

Net margin-597%-194pp

FCF margin-550.2%-140pp

Returns & leverage

See full

Return on equity-56.3%-1.5pp

Debt / equity0.1×0.0×

Current ratio6.1×+1.2×

Where this comes from

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Intellia Therapeutics's financing cash flow?: Intellia Therapeutics (NTLA) reported financing cash flow of $33.57M in Q1 2026.
What is the long-term trend for Intellia Therapeutics's financing cash flow?: Over 4 years (2021 to 2025), Intellia Therapeutics's financing cash flow has grown at a -35.0% compound annual growth rate (CAGR), from $736.69M to $131.49M.
What does financing cash flow mean?: Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.